Agarose Bead Technologies (ABT) has announced plans for further expansion, reinforcing its position as a strategic partner for biopharmaceutical companies developing next-generation therapies. For 25 years, ABT has worked alongside biotech and pharma companies to provide scalable and reproducible chromatography solutions that are critical to the development and manufacturing of innovative therapies. It also plans to extend its expertise in tailor-made solutions by offering a design and manufacture of customized resins service for other biopharmaceutical companies.

ABT's agarose resins are widely applied in the purification of monoclonal antibodies (mAbs), advanced cell and gene therapies (ATMPs), lipid nanoparticles (LNPs), recombinant proteins and therapeutic oligonucleotides. Following the $5m investment in the expansion of its Burgos facility last year, ABT now has its sights set on expanding its global presence in new international markets, including India and the US.

Pilar Armisen, Business & Technical Development said: "As we celebrate our 25th anniversary, it's incredible to reflect on how far we've come as a business. We are the only resin manufacturer in Spain and we have played a significant role in the evolution of agarose resins."

Today, in addition to performing at the research level, agarose resins deliver on scalability, reproducibility, regulatory compliance and cost-effectiveness for large-scale GMP manufacturing. They are a critical component in global health, helping to bring innovative therapies to patients around the world. Armisen continued: "Reaching our 25th anniversary is both a proud moment and a springboard for the future. Looking ahead, we plan to invest approximately $10m during the next five years to expand our capabilities and strengthen our role as a partner of choice for companies developing biologics and advanced therapies. Today's innovators don't just need products; they need a trusted partner who can provide unique, flexible and scalable solutions for the purification of molecules, whatever their nature. At ABT, we see our role as enabling these therapies to move from idea to impact, helping ensure patients around the world gain access to life-changing treatments".

The company supplies customized matrices and high-quality products for protein and antibody purification, supporting process scale-up and technology transfer. ABT emphasizes compliance with regulatory standards and good manufacturing practices, ensuring traceability and reproducibility of critical materials.

Expansion includes new facilities and supply-chain improvements to meet growing demand and reduce lead times. This strengthens ABT's position in international markets and its ability to serve the biopharma industry across development and commercial production.